Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)

Trial Details

NCT ID
NCT05783609
Phase
PHASE2
Sponsor
Reid Merryman, MD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Epcoritamab
  • Rituximab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Rochester, New York, United States|43.15478,-77.61556
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) with review of the diagnostic pathology specimen at one of the participating institutio…
  • No prior systemic therapy for FL. Prior treatment with radiation therapy or short course steroids is allowed.
  • Meets at least one criterion to begin treatment based on the modified GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria:
  • Symptomatic adenopathy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →